Octreotide (Immediate release)

Phase 2

Novartis AG (NVS)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Peritoneal Neoplasms

View Full Landscape

Drug Information

Target Indication

Peritoneal Neoplasms

Clinical Trial

NCT00332696

Last updated: 3/17/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA6/30/2025

Oczyesa

Oczyesa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.

View on EMA

EMA12/2/2022

Mycapssa

Mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

NVS

Novartis AG

Pharmaceutical Preparations•Europe•NYSE

Related Pipeline

Benazepril plus hydrochlorothiazidePhase 3

Hypertension

Verteporfin PDTPhase 3

Pathological Myopia